SIDEBAR: Should EGFR Tyrosine Kinase Inhibitors Be Continued Beyond Progression?


Get Permission

It is not yet clear if it is beneficial to continue first-line EGFR tyrosine kinase inhibitors in patients with EGFR-mutated lung cancer who experience progression and are started on chemotherapy, according to Dr. Horn. Two trials, one in Asia (looking at gefitinib [Iressa]) and one in North America (looking at erlotinib [Tarceva]), will be evaluating outcomes with this practice.

“There has been compelling data published on the flare phenomenon in patients who are on a first-line EGFR [tyrosine kinase inhibitor] who stop therapy,” she noted. “Right now, there are no great data to say you should continue the EGFR [tyrosine kinase inhibitor] and add chemotherapy. What I tend to do is either tell the patients to stop the [tyrosine kinase inhibitor] the day they start chemotherapy, to sort of prevent that flare phenomenon, or I just let them finish out their bottle if they have got another 2 weeks’ supply, just let them continue on the [tyrosine kinase inhibitor] while you initiate chemotherapy.” ■


Related Articles

New Therapies Capitalize on Lung Cancer’s Molecular Vulnerabilities

Research reported at this year’s ASCO Annual Meeting attests to the tremendous molecular diversity of non–small cell lung cancer (NSCLC) and the power of appropriately selected treatment, according to Leora Horn, MD, of Vanderbilt University Medical Center, who presented data on molecular findings...

SIDEBAR: Molecular Testing Requires Planning at Time of Biopsy

The molecular analysis of lung cancer patients is becoming more and more complex,” and clinicians therefore need to consider any additional tissue requirements upfront, Dr. Horn commented.

At Vanderbilt University, testing for EGFR, KRAS, and eight other mutations is done using the Lung SnaPshot...


Advertisement

Advertisement



Advertisement